NCT02706353 2025-11-21APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaM.D. Anderson Cancer CenterPhase 1/2 Terminated34 enrolled 18 charts
NCT04337931 2024-02-13A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic MelanomaApexigen America, Inc.Phase 2 Terminated45 enrolled 14 charts